US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Roche Holding Ltd

38.95

-1.3800-3.42%

Volume:1.33M

Turnover:52.33M

Market Cap:252.16B

PE:25.11

High:39.81

Open:39.77

Low:38.63

Close:40.33

Loading ...

Overview Company News Filings

Genentech announces FDA acceptance of Columvi combination sBLA

NVCR Stock Up as TTFields Therapy Meets Pancreatic Cancer Study Goals

The Zacks Analyst Blog Highlights Roche, Poseida Therapeutics, Merck, AstraZeneca and Novartis

Pharma Stock Roundup: RHHBY to Buy PSTX, MRK, AZN See Pipeline Success

Sarepta Therapeutics Stock Surges 43% YTD: How to Play the Stock?

SRPT Inks $11B Licensing Deal With Arrowhead for Rare Gene Therapies

Arcus anti-TIGIT antibody differentiated from Roche’s, says Barclays

Why This Gene-Therapy Company's Stock Is Rising 228% -- Barrons.com

Roche to Acquire CAR-T Cell Therapy Focused Poseida for $1.5B

Trending: Roche to Buy Poseida Therapeutics for Up to $1.5 Billion

Poseida downgraded to Market Perform from Outperform at William Blair

Roche anti-TIGIT therapy fails to extend survival in late-stage lung cancer trial

Poseida Therapeutics Shares Triple on Roche Acquisition Worth Up to $1.5B

Roche reports SKYSCRAPER-01 study misses primary endpoint

Poseida Therapeutics to be acquired by Roche for $9.00 per share plus CVR

Roche's Lung-Cancer Trial Failure Doesn't Surprise -- Market Talk

Roche to Acquire Poseida Therapeutics in a Deal Worth Up to $1.5 Billion -- Update

Roche announces FDA approval of label expansion into biliary tract cancer

Viking Therapeutics a new buy at B Riley on lead obesity asset VK2735

Nvidia Says BioNeMo Framework Will Advance Drug Discovery

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/RHHBY/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RHHBY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RHHBY\",,,,,undefined,":{"symbol":"RHHBY","market":"US","secType":"STK","nameCN":"Roche Holding Ltd","latestPrice":38.95,"timestamp":1746720120000,"preClose":40.33,"halted":0,"volume":1331912,"delay":15,"floatShares":6374000000,"shares":6474029800,"eps":1.550894,"marketStatus":"Trading","change":-1.38,"latestTime":"05-08 12:02:00 EDT Delay","open":39.77,"high":39.81,"low":38.63,"amount":52334285.4512,"amplitude":0.029259,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":1.550894,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1746734400000},"marketStatusCode":2,"adr":0,"adrRate":0.125,"exchange":"OTCQX","adjPreClose":40.33,"volumeRatio":1.383087},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RHHBY\",,,,,undefined,":{"symbol":"RHHBY","floatShares":6374000000,"roa":"12.75%","roe":"26.47%","lyrEps":2.136203,"volumeRatio":1.383087,"shares":6474029800,"dividePrice":1.461574,"high":39.81,"amplitude":0.029259,"preClose":40.33,"low":38.63,"week52Low":30.06,"pbRate":"6.59","psRate":"3.35","week52High":44.31,"institutionHeld":0,"latestPrice":38.95,"eps":1.550894,"divideRate":0.037524,"volume":1331912,"delay":15,"ttmEps":1.550894,"open":39.77,"prevYearClose":34.88,"prevWeekClose":41.08,"prevMonthClose":40.77,"prevQuarterClose":41.15,"fiveDayClose":39.58,"twentyDayClose":37.1,"sixtyDayClose":39.43},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RHHBY\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2489443677","title":"Genentech announces FDA acceptance of Columvi combination sBLA","url":"https://stock-news.laohu8.com/highlight/detail?id=2489443677","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489443677?lang=en_us&edition=fundamental","pubTime":"2024-12-05 18:30","pubTimestamp":1733394626,"startTime":"0","endTime":"0","summary":"Genentech, a member of Roche (RHHBY), announced that the FDA has accepted the company’s supplemental biologics license application, or sBLA, for Co...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/genentech-announces-fda-acceptance-of-columvi-combination-sbla?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/genentech-announces-fda-acceptance-of-columvi-combination-sbla?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["03165","BK4007","RHHBY"],"gpt_icon":0},{"id":"2488923421","title":"NVCR Stock Up as TTFields Therapy Meets Pancreatic Cancer Study Goals","url":"https://stock-news.laohu8.com/highlight/detail?id=2488923421","media":"Zacks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488923421?lang=en_us&edition=fundamental","pubTime":"2024-12-03 22:56","pubTimestamp":1733237760,"startTime":"0","endTime":"0","summary":"Novocure LimitedNVCR announced meeting the primary endpoint of overall survival  in a late-stage study, which evaluated the use of Tumor Treating Fields  therapy concomitantly with chemotherapy regimen as a first-line treatment for unresectable, locally advanced pancreatic adenocarcinoma. Shares of the company gained 49% on Monday in response to the encouraging news.TTFields are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. The phase III PANOVA-3 evaluated the efficacy and safety ofTTFields therapy in combination with standard-of-care  chemotherapy  to treat pancreatic cancer patients. The enrolled patient population was randomized equally into two arms to receive either the combo regimen or SoC chemotherapy alone  and followed for atleast 18 months.Pancreatic cancer is one of the deadliest cancers and the third leading cause of cancer-related deaths in the United States. While overall cancer rates remaining stable or declining, pancreatic","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/kHYuj_GDhroF7BEQsCcsVA--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4658663242c3a61dee3fef55a1bf4887","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/kHYuj_GDhroF7BEQsCcsVA--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4658663242c3a61dee3fef55a1bf4887"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nvcr-stock-ttfields-therapy-meets-145600302.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BLSP4452.SGD","IE000M9KFDE8.USD","IE00B19Z3B42.SGD","RHHBY","BK4592","BK4581","LU1023059063.AUD","LU1894683348.USD","SG9999013999.USD","LU0058720904.USD","LU0889565916.HKD","LU2468319806.SGD","BK4007","BK4082","LU2087621335.USD","LU0170899867.USD","SG9999002224.SGD","03165","BK4578","GILD","LU1585245621.USD","IE00BLSP4239.USD","BK4566","LU1571399168.USD","BK4139","OS","SG9999001176.SGD","SG9999011175.SGD","IE0002270589.USD","BK4534","BK4097","BK4532","LU0234570918.USD","BK4533","LU0456855351.SGD","NVCR","BK4568","SG9999002232.USD","LU0985481810.HKD","LU0109394709.USD","IE00BSNM7G36.USD","LU1839511570.USD","LU1066053197.SGD","LU1057294990.SGD","PFE","BK4550","IE00BZ1G4Q59.USD","LU1066051498.USD","LU0225284248.USD","BK4548"],"gpt_icon":1},{"id":"2488954151","title":"The Zacks Analyst Blog Highlights Roche, Poseida Therapeutics, Merck, AstraZeneca and Novartis","url":"https://stock-news.laohu8.com/highlight/detail?id=2488954151","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488954151?lang=en_us&edition=fundamental","pubTime":"2024-12-02 18:00","pubTimestamp":1733133600,"startTime":"0","endTime":"0","summary":"Chicago, IL – December 2, 2024 – Zacks.com announces the list of Stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Roche RHHBY, Poseida Therapeutics PSTX, Merck MRK, AstraZeneca AZN and Novartis NVS.This week, Roche announced that it will acquire its existing partner, Poseida Therapeutics for $9 per share in cash, representing a total equity value of approximately $1.0 billion. Merck and AstraZeneca’s late-stage studies, evaluating the expanded use of their new drugs, met their respective goals. The European Commission approved Novartis’ breast cancer drug Kisqali  for a broad population in early breast cancer.Based on the overwhelming efficacy seen in the study, an independent data monitoring committee  recommended the study be stopped early. The DMC also recommended that patients with this advanced form of PAH be offered the oppo","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/6pmiwRZRhtc7hxDNA3zxVQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ef77d5a5eb4e72e4dd31ccfaf4ca4ccd","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/6pmiwRZRhtc7hxDNA3zxVQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ef77d5a5eb4e72e4dd31ccfaf4ca4ccd"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zacks-analyst-blog-highlights-roche-100000082.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4211","IE00BFTCPJ56.SGD","BK4588","LU0965508806.USD","SG9999014567.USD","LENZ","LU1066051498.USD","03165","SGXZ57979304.SGD","LU0203345920.USD","LU2023250843.SGD","LU1057294990.SGD","BK4123","LU1430594728.SGD","FC","NVS","BK4201","PSTX","LU1061106388.HKD","MBC","SG9999014559.SGD","BK4161","LU0965509010.AUD","LU1585245621.USD","LU1291159041.SGD","RHHBY","IE00B2B36J28.USD","BK4139","SG9999002232.USD","LU1934455863.HKD","MRK","CVR","LU0203347892.USD","LU2106854487.HKD","LU1829250122.USD","AZN","EBC","LU2089984988.USD","ADT","SG9999001176.SGD","IE000M9KFDE8.USD","LU1037948541.HKD","IE00BN8TJ469.HKD","LU0965509101.SGD","LU1037948897.HKD","LU2112291526.USD","EC","LU0109394709.USD","LU0208291251.USD","IE00BJT1NW94.SGD"],"gpt_icon":1},{"id":"2487151878","title":"Pharma Stock Roundup: RHHBY to Buy PSTX, MRK, AZN See Pipeline Success","url":"https://stock-news.laohu8.com/highlight/detail?id=2487151878","media":"Zacks","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2487151878?lang=en_us&edition=fundamental","pubTime":"2024-11-30 04:00","pubTimestamp":1732910400,"startTime":"0","endTime":"0","summary":"Roche announced plans to acquire Poseida Therapeutics for about $1 billion.Merck, AstraZeneca and Novartis have all seen success in studies of new drugs in their pipelines.This week, Roche RHHBY announced that it will acquire its existing partner, Poseida Therapeutics PSTX for $9 per share in cash, representing a total equity value of approximately $1.0 billion. Merck MRK and AstraZeneca’s AZN late-stage studies, evaluating the expanded use of their new drugs, met their respective goals. The European Commission approved Novartis’ NVS breast cancer drug Kisqali  for a broad population in early breast cancer.Based on the overwhelming efficacy seen in the study, an independent data monitoring committee  recommended the study be stopped early. The DMC also recommended that patients with this advanced form of PAH be offered the opportunity to get Winrevair through an open-label extension study.Roche announced a definitive agreement to acquire Poseida Therapeutics, a biotech making allogenei","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/VTpWEp9iphTX3xsYcMogbg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ca9d72216d7bb42fc496430c3df29b41","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/VTpWEp9iphTX3xsYcMogbg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ca9d72216d7bb42fc496430c3df29b41"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pharma-stock-roundup-rhhby-buy-200000767.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BJJMRZ35.SGD","IE0009355771.USD","IE00BBT3K403.USD","LU1934455194.USD","LU1934455863.HKD","NVS","LU1037948541.HKD","CVR","LU1934455277.USD","BK4201","LU0320765489.SGD","IE00BJT1NW94.SGD","LU1116320901.HKD","SG9999001176.SGD","LU0238689110.USD","SG9999002232.USD","BK4534","ADT","LU2112291526.USD","LU0320765992.SGD","SG9999001440.SGD","LU2089984988.USD","LU0889565916.HKD","AZN","EBC","LU0070302665.USD","LU1093756168.USD","BK4139","MRK","SG9999014567.USD","PSTX","BK4086","LU2468319806.SGD","03165","LU0122379950.USD","EC","LU0058720904.USD","LU0965509101.SGD","LU0208291251.USD","LU1989772923.USD","BK4559","FC","LU2417539215.USD","LU0289739699.SGD","MBC","RHHBY","SGXZ57979304.SGD","BK4585","LU1023059063.AUD","LU2361044949.HKD"],"gpt_icon":1},{"id":"2487027592","title":"Sarepta Therapeutics Stock Surges 43% YTD: How to Play the Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2487027592","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2487027592?lang=en_us&edition=fundamental","pubTime":"2024-11-30 02:59","pubTimestamp":1732906740,"startTime":"0","endTime":"0","summary":"Shares of Sarepta Therapeutics SRPT have soared 43% year to date, significantly outperforming the industry’s 6.9% decline. The stock has also underperformed the sector and the S&P 500 during the same period, as shown in the chart below. SRPT’s shares are trading above the 50 and 200-day moving averages.The surge in the stock price can be attributed to the encouraging sales performance of Duchenne muscular dystrophy  gene therapy Elevidys.Currently, Elevidys is the first and only one-shot gene therapy for DMD in the United States. Since its commercial launch in June 2023, the therapy has demonstrated blockbuster potential.Sarepta is evaluating another investigational gene therapy, SRP-6004, in an early-stage study for ambulatory patients living with LGMD type 2B/R2 . It intends to start two clinical studies on SRP-9004 to treat LGMD type 2D and SRP-9005 in LGMD type 2C by 202","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sarepta-therapeutics-stock-surges-43-185900018.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RHHBY","BK4007","BK4139","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","IE0009355771.USD","03165","IE00BJT1NW94.SGD","BK4585","SRPT","IE00BJJMRZ35.SGD","IE0002141913.USD"],"gpt_icon":0},{"id":"2486380364","title":"SRPT Inks $11B Licensing Deal With Arrowhead for Rare Gene Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2486380364","media":"Zacks","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486380364?lang=en_us&edition=fundamental","pubTime":"2024-11-28 00:31","pubTimestamp":1732725060,"startTime":"0","endTime":"0","summary":"Shares of Sarepta Therapeutics SRPT rose nearly 14% on Tuesday after announcing that it has entered into an exclusive global licensing and collaboration agreement with Arrowhead Pharmaceuticals ARWR.Per the deal terms, Sarepta will acquire exclusive rights to Arrowhead’s seven pipeline programs, which include four in active clinical development and the remaining three in preclinical development. These programs are being developed against a broad range of genetic diseases in muscle, central nervous system  and rare pulmonary disorders.Arrowhead will remain responsible for the ongoing clinical studies. Once these studies are complete, Sarepta will assume responsibility for the later stages of development.Sarepta will assume responsibility for three preclinical assets following the completion of the investigational new drug -enabling activities by Arrowhead. These programs target spinocerebellar ataxia type 1, spinocerebellar ataxia type 3 and Huntington's disease.As part of this deal, th","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/srpt-inks-11b-licensing-deal-163100788.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BJJMRZ35.SGD","ARWR","03165","CNS","IE0002141913.USD","BK4139","RHHBY","IE00BJT1NW94.SGD","BK4135","BK4007","IE0009355771.USD","IE00BFTCPJ56.SGD","SRPT","BK4585","IE00B2B36J28.USD"],"gpt_icon":0},{"id":"2486884422","title":"Arcus anti-TIGIT antibody differentiated from Roche’s, says Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2486884422","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486884422?lang=en_us&edition=fundamental","pubTime":"2024-11-27 18:55","pubTimestamp":1732704917,"startTime":"0","endTime":"0","summary":"Barclays says Roche’s (RHHBY) SKY-01 failure is not totally unexpected but likely to be seen as a negative read-through for anti-TIGIT space. Howev...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/arcus-anti-tigit-antibody-differentiated-from-roches-says-barclays?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/arcus-anti-tigit-antibody-differentiated-from-roches-says-barclays?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","03165","RHHBY"],"gpt_icon":0},{"id":"2486882208","title":"Why This Gene-Therapy Company's Stock Is Rising 228% -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2486882208","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486882208?lang=en_us&edition=fundamental","pubTime":"2024-11-27 00:10","pubTimestamp":1732637400,"startTime":"0","endTime":"0","summary":"Poseida Therapeutics stock skyrocketed Tuesday after Roche closed a deal to acquire the California-based biopharmaceutical company.Shares of the cell-therapy company, which develops off-the-shelf treatments for cancer, were up 228% to $9.37. The stock was on pace for its best one-day gain on record, according to Dow Jones Market Data.Roche, a Swiss healthcare company, agreed to pay $9 a share in cash at closing. Poseida stockholders also will receive a non-tradeable contingent value right for up to $4 per share based on \"achievement of specific milestones,\" boosting the value of the deal to around $1.5 billion.The transaction, which is expected to wrap up in the first quarter of 2025, will help Roche \"drive further progress in allogenic cell therapy, \" according to Chief Medical Levi Garraway.\"We have worked closely with Roche through our collaboration focused on hematologic malignancies, and we are excited to join Roche to work as colleagues together across our pipeline and future pro","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PSTX","RHHBY","03165"],"gpt_icon":0},{"id":"2486884715","title":"Roche to Acquire CAR-T Cell Therapy Focused Poseida for $1.5B","url":"https://stock-news.laohu8.com/highlight/detail?id=2486884715","media":"Zacks","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486884715?lang=en_us&edition=fundamental","pubTime":"2024-11-26 23:59","pubTimestamp":1732636740,"startTime":"0","endTime":"0","summary":"Shares of PSTX are up in pre-market trading on the acquisition news.Roche’s shares have lost 1.6% year to date against the industry’s growth of 6.4%.Per the terms, Roche will initiate a tender offer to acquire all of the outstanding shares of Poseida common stock for $9.00 per share in cash. PSTX’s stockholders would also receive a non-tradeable contingent value right  for up to an aggregate of $4.00 per share in cash, representing a total deal value of up to approximately $1.5 billion.The offer price of $9 represents a premium of approximately 215% to Poseida’s closing share price on Nov. 25, 2024.California-based Poseida’s R&D portfolio includes pre-clinical and clinical-stage off-the-shelf  CAR-T therapies across several therapeutic areas, including hematological malignancies, solid tumors and autoimmune disease, as well as manufacturing capabilities and technology platforms.Roche is currently looking to augment its pipeline after facing a few pipeline setbacks a couple of years ago","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/H9DYdttPy00EKBHhcxtlCA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9f2a2e04a053cda7a8c096e532e43d28","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/H9DYdttPy00EKBHhcxtlCA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9f2a2e04a053cda7a8c096e532e43d28"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/roche-acquire-car-t-cell-155900367.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0456855351.SGD","LU1066051498.USD","BK4532","LU0985481810.HKD","RHHBY","IE00BLSP4452.SGD","IE00BKVL7J92.USD","LU1057294990.SGD","LU0109394709.USD","IE00BBT3K403.USD","LU1894683348.USD","CVR","BK4533","BK4534","SG9999001176.SGD","LU0306806265.USD","IE00B19Z3B42.SGD","BK4007","PSTX","CAR","IE00B19Z3581.USD","LU2087621335.USD","SG9999013999.USD","BK4161","IE000M9KFDE8.USD","IE00BLSP4239.USD","BK4578","IE0002270589.USD","LU0225771236.USD","LU0320765992.SGD","LU1066053197.SGD","LU0321505439.SGD","LU0234572021.USD","LU1571399168.USD","SG9999002224.SGD","LU0170899867.USD","IE00BSNM7G36.USD","LU0289739699.SGD","BK4568","SG9999003800.SGD","LU1023059063.AUD","LU0122379950.USD","PFE","BK4583","BK4592","03165","SG9999002232.USD","GILD","LU0889565916.HKD","LU0058720904.USD"],"gpt_icon":1},{"id":"2486002310","title":"Trending: Roche to Buy Poseida Therapeutics for Up to $1.5 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2486002310","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486002310?lang=en_us&edition=fundamental","pubTime":"2024-11-26 23:12","pubTimestamp":1732633920,"startTime":"0","endTime":"0","summary":"10:12 ET -- Roche is one of the most mentioned companies in the U.S. across all news items in the past 12 hours, according to Factiva data. Roche agreed to buy San Diego-based Poseida Therapeutics in a deal worth up to $1.5 billion, as the company seeks to expand its pipeline and support growth. The deal allows the Swiss pharmaceutical company to bring in house its current partner with the aim of developing cell therapies in oncology, immunology and neurology. Roche is buying Poseida Therapeutics for about $1 billion, or $9 a share, with additional performance-related payments worth up to $4 a share that could take the full deal value to around $1.5 billion. Poseida shares closed at $2.86 Monday. Dow Jones & Co. owns Factiva. ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSTX","BK4007","RHHBY","03165","LENZ","BK4139"],"gpt_icon":0},{"id":"2486005312","title":"Poseida downgraded to Market Perform from Outperform at William Blair","url":"https://stock-news.laohu8.com/highlight/detail?id=2486005312","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486005312?lang=en_us&edition=fundamental","pubTime":"2024-11-26 21:46","pubTimestamp":1732628789,"startTime":"0","endTime":"0","summary":"William Blair downgraded Poseida Therapeutics (PSTX) to Market Perform from Outperform after Roche (RHHBY) agreed to acquire Poseida for $13 per sh...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/poseida-downgraded-to-market-perform-from-outperform-at-william-blair?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/poseida-downgraded-to-market-perform-from-outperform-at-william-blair?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PSTX","BK4007","RHHBY","03165"],"gpt_icon":0},{"id":"2486077209","title":"Roche anti-TIGIT therapy fails to extend survival in late-stage lung cancer trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2486077209","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486077209?lang=en_us&edition=fundamental","pubTime":"2024-11-26 19:53","pubTimestamp":1732621994,"startTime":"0","endTime":"0","summary":"Michael Vi/iStock Editorial via Getty ImagesGenentech, a unit of Roche , announced Tuesday that its anti-TIGIT immunotherapy tiragolumab as part of a combination regimen failed to reach the primary endpoint of overall survival in a late-stage trial for certain patients with lung cancer. The outcome","market":"sh","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1181551537/image_1181551537.jpg?io=getty-c-w750","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1181551537/image_1181551537.jpg?io=getty-c-w750"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4334239-roche-anti-tigit-drug-fails-lung-cancer-trial","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["03165","BK4007","RHHBF","RHHBY"],"gpt_icon":0},{"id":"2486076449","title":"Poseida Therapeutics Shares Triple on Roche Acquisition Worth Up to $1.5B","url":"https://stock-news.laohu8.com/highlight/detail?id=2486076449","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486076449?lang=en_us&edition=fundamental","pubTime":"2024-11-26 19:52","pubTimestamp":1732621920,"startTime":"0","endTime":"0","summary":"Shares of Poseida Therapeutics tripled after the company agreed to be acquired by Roche in a deal worth up to $1.5 billion.The stock was changing hands at $9.21 in premarket trading on Tuesday. Shares closed yesterday's trading session at $2.86.The clinical-stage cell and gene therapy company said Tuesday that it would be acquired for about $1 billion, or $9 a share, and additional performance-related payments worth up to $4 a share.The two companies have been working together since 2022 to develop CAR-T cell therapies for patients with hematological malignancies.Roche is also acquiring Poseida Therapeutics' other cell-therapy candidates as well as related manufacturing capabilities and platform technologies.The transaction is expected to complete in the first quarter of 2025.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RHHBY","03165","PSTX","LENZ","BK4007","BK4139"],"gpt_icon":0},{"id":"2486895020","title":"Roche reports SKYSCRAPER-01 study misses primary endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2486895020","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486895020?lang=en_us&edition=fundamental","pubTime":"2024-11-26 18:30","pubTimestamp":1732617028,"startTime":"0","endTime":"0","summary":"Genentech, a member of the Roche (RHHBY), reported an update on the Phase III SKYSCRAPER-01 study, evaluating tiragolumab combined with Tecentriq c...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roche-reports-skyscraper-01-study-misses-primary-endpoint?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roche-reports-skyscraper-01-study-misses-primary-endpoint?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","03165","RHHBY"],"gpt_icon":0},{"id":"2486020823","title":"Poseida Therapeutics to be acquired by Roche for $9.00 per share plus CVR","url":"https://stock-news.laohu8.com/highlight/detail?id=2486020823","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486020823?lang=en_us&edition=fundamental","pubTime":"2024-11-26 18:25","pubTimestamp":1732616716,"startTime":"0","endTime":"0","summary":"Poseida Therapeutics (PSTX) announced that it has entered into a merger agreement to be acquired by Roche (RHHBY) at a price of $9.00 per share in ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/poseida-therapeutics-to-be-acquired-by-roche-for-9-00-per-share-plus-cvr?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/poseida-therapeutics-to-be-acquired-by-roche-for-9-00-per-share-plus-cvr?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSTX","CVR","RHHBY","BK4161","03165","BK4139","LENZ","BK4007"],"gpt_icon":0},{"id":"2486021567","title":"Roche's Lung-Cancer Trial Failure Doesn't Surprise -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2486021567","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486021567?lang=en_us&edition=fundamental","pubTime":"2024-11-26 17:41","pubTimestamp":1732614060,"startTime":"0","endTime":"0","summary":"0941 GMT - News that Roche's tiragolumab drug candidate didn't meet the primary goal of a late-stage clinical trial in lung cancer doesn't come as a surprise for investors, Bryan Garnier says in a note. The Swiss pharmaceutical company released long-awaited data at final analysis for tiragolumab that showed the overall survival goal wasn't met. This was largely anticipated by the market in light of previous data, Bryan Garnier says. Roche had previously pointed at a limited efficacy in terms of progression-free survival and a miss relative to Merck's Keytruda in a separate arm of the same clinical program, the broker says. Shares fall 1%.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4534","LU1974910355.USD","LU1061106388.HKD","LU1093756325.SGD","LU1116320901.HKD","LU1291159041.SGD","IE00BSNM7G36.USD","LU1941712348.USD","03165","IE00B1BXHZ80.USD","LU0211331839.USD","IE00BN8TJ469.HKD","LU1093756168.USD","IE00BLSP4452.SGD","LU1066051811.HKD","SG9999002224.SGD","LU2324357040.USD","LU0203347892.USD","LU0106261372.USD","LU0208291251.USD","SG9999014575.USD","LU0070302665.USD","LU1066053197.SGD","SG9999001176.SGD","LU1066051225.USD","LU2023250504.SGD","MRK","LU1917777945.USD","LU0965508806.USD","LU0234572021.USD","LU0265550359.USD","LU0006306889.USD","LU0266013472.USD","LU1934455863.HKD","IE00BJT1NW94.SGD","LU1989771016.USD","LU0861579265.USD","LU2106854487.HKD","LU1934455194.USD","IE000M9KFDE8.USD","LU2361045086.USD","RHHBY","LU0965509010.AUD","IE00BFTCPJ56.SGD","BK4550","IE0009355771.USD","LU2023250843.SGD","LU1116320737.USD","SG9999002232.USD","BK4588"],"gpt_icon":0},{"id":"2486602359","title":"Roche to Acquire Poseida Therapeutics in a Deal Worth Up to $1.5 Billion -- Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2486602359","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486602359?lang=en_us&edition=fundamental","pubTime":"2024-11-26 16:40","pubTimestamp":1732610400,"startTime":"0","endTime":"0","summary":"Roche agreed to buy San Diego-based Poseida Therapeutics in a deal worth up to $1.5 billion, as the company seeks to expand its pipeline and support growth.The deal allows the Swiss pharmaceutical company to bring in house its current partner with the aim of developing cell therapies in oncology, immunology and neurology. The move is part of Roche's efforts to replenish its drug pipeline and drive sales growth toward the end of the decade.Roche said Tuesday that it entered into a definitive merger agreement to acquire Poseida Therapeutics for about $1 billion, or $9 a share, with additional performance-related payments worth up to $4.00 a share that could take the full deal value to around $1.5 billion. Poseida shares closed at $2.86 on Monday.The two companies have been working together since 2022 to develop CAR-T cell therapies for patients with hematological malignancies.CAR-T cell therapies are customized for individual patients and are made by collecting a patient's own T cells, a","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PSTX","BK4007","RHHBY","03165","LENZ"],"gpt_icon":1},{"id":"2486070190","title":"Roche announces FDA approval of label expansion into biliary tract cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2486070190","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486070190?lang=en_us&edition=fundamental","pubTime":"2024-11-25 18:35","pubTimestamp":1732530951,"startTime":"0","endTime":"0","summary":"Roche (RHHBY) announced the FDA approval of a label expansion into biliary tract cancer, or BTC, for the Pathway anti-HER2/neu Rabbit Monoclonal Pr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roche-announces-fda-approval-of-label-expansion-into-biliary-tract-cancer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roche-announces-fda-approval-of-label-expansion-into-biliary-tract-cancer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BTCmain","RHHBY","BK4007","XBTmain","03165"],"gpt_icon":0},{"id":"2485267716","title":"Viking Therapeutics a new buy at B Riley on lead obesity asset VK2735","url":"https://stock-news.laohu8.com/highlight/detail?id=2485267716","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485267716?lang=en_us&edition=fundamental","pubTime":"2024-11-22 23:20","pubTimestamp":1732288809,"startTime":"0","endTime":"0","summary":"Michail_Petrov-96/iStock via Getty Images B Riley has initiated Viking Therapeutics at buy saying that the company lead obesity treatment, VK2735, could have \"long-term disruptive potential.\" The investment bank has a $109 price target . Analyst Mayank Mamtani said that VK2735 could set itself apart from existing weight loss drugs as it is a \"GLP1/GIP agonist being developedfor an induction  and maintenance  paradigm.\"  Despite VK2735 demonstrating strong clinical results so far, the stock is down ~50% off its 52-week high, he noted, adding that upcoming \"additional visibility into manufacturing capacity and competitive positioning [could] unlock significant value through YE 2025E.\" And while Viking's drug is competing against other candidates, such as Novo Nordisk's  CagriSema, Amgen's  MariTide, and Roche's  GYM329, data updates from these programs \"represent an opportunity, in our opinion, for VK2735's unique positioning to further stand out while bringing into focus the broader por","market":"fut","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/654548316/image_654548316.jpg?io=getty-c-w750","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/654548316/image_654548316.jpg?io=getty-c-w750"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4321443-viking-therapeuticsanewbuyat-b-rileyonleadobesityasset-vk-2735","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["03165","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","BK4139","NVO.AU","SG9999001440.SGD","IE00BFTCPJ56.SGD","IE0009355771.USD","LU0154236417.USD","LU1057294990.SGD","BK4532","LU2242652126.USD","LU0058720904.USD","LU1023059063.AUD","BK4599","LU1571399168.USD","RHHBY","IE0002141913.USD","LU1983299246.USD","LU1093756168.USD","BK4533","IE00BKVL7J92.USD","NVO","LU0109394709.USD","IE00B4R5TH58.HKD","BK4007","LU1093756325.SGD","AMGN","LU0889565916.HKD","LU0122379950.USD","BK7104","IE00B2B36J28.USD","BK4534","LU1061106388.HKD","LU0289739699.SGD","LU0868494617.USD","IE00BZ1G4Q59.USD","BK4566","LU2242646821.SGD","LU2112291526.USD","BK4585","BK4581","LU0320765992.SGD","BK4588","VKTX"],"gpt_icon":1},{"id":"2484760720","title":"Nvidia Says BioNeMo Framework Will Advance Drug Discovery","url":"https://stock-news.laohu8.com/highlight/detail?id=2484760720","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484760720?lang=en_us&edition=fundamental","pubTime":"2024-11-19 03:11","pubTimestamp":1731957060,"startTime":"0","endTime":"0","summary":"Nvidia said companies across industries are adopting its open-source BioNeMo framework, which offers computing tools designed to help artificial intelligence advance drug discovery and accelerate molecule design.These companies, from sectors including pharma, biotech and academia, include Argonne National Laboratory, Roche Group's Genentech and Weights & Biases, the tech company said Monday. More than 200 users have integrated the framework into their workflows.The framework uses accelerated computing infrastructure to reduce costs, increase scale and speed up drug discovery workflows by providing insights from biomolecular data, the company said.Vice President of healthcare Kimberly Powell said recent Nobel Prize wins in chemistry demonstrate AI and advanced computing ability to contribute to the pharmaceutical industry. \"To help unravel the complexities of biological systems, we've introduced the open-source BioNeMo Framework, which will enable researchers world-wide to accelerate th","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"9b91bc36a41ca6f2915504b9e6e5cc51","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVDS","LU1066053197.SGD","LU1623119135.USD","LU2237438978.USD","3NVD.UK","LU2417539215.USD","NVD3.UK","LU0234570918.USD","2NVD.UK","BK4581","SG9999014542.SGD","LU2552382132.HKD","NVDS.UK","LU0882574139.USD","LU2237957902.USD","LU2433249047.HKD","LU0124676726.USD","LU0943347566.SGD","RHHBY","LU0203202063.USD","LU0276348264.USD","IE00BDCRKT87.USD","NVDA","LU1280957306.USD","SNVD.UK","LU2294711713.HKD","SGXZ81514606.USD","NVDD","LU1496350502.SGD","NVDY","NVD","IE00B19Z9505.USD","NVD2.UK","LU0689472784.USD","LU2361045086.USD","BK4141","NVDX","LU2125909247.SGD","IE00B775H168.HKD","LU1861215975.USD","NVDU","LU0889565833.HKD","LU1674673428.USD","03165","IE0009356076.USD","LU1069344957.HKD","LU2552382058.USD","LU0348723411.USD","LU1064131342.USD"],"gpt_icon":1}],"pageSize":20,"totalPage":7,"pageCount":6,"totalSize":124,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RHHBY\",params:#limit:5,,,undefined,":[{"date":"2025-03-28","symbol":"RHHBY","amount":0.855932,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-28","defaultRemindTime":1743168600000,"name":"罗氏控股","lastCurrency":null,"lastExecuteDate":null,"recordDate":null,"payableDate":"2025-03-28","currency":"USD","dateTimestamp":1743134400000,"payDate":null},{"date":"2024-07-25","symbol":"RHHBY","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1721894400000,"name":null,"time":"","dateTimestamp":1721880000000,"actualEps":null},{"date":"2024-03-14","symbol":"RHHBY","amount":0.8751559,"announcedDate":null,"type":"dividend","market":"US","newRecordDate":"2024-03-15","defaultRemindTime":1710423000000,"name":"罗氏控股","recordDate":null,"payableDate":"2024-03-15","currency":"USD","dateTimestamp":1710388800000,"payDate":null},{"market":"US","date":"2024-02-01","symbol":"RHHBY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1706763600000,"reportTimeType":"","actualEps":null},{"date":"2023-07-27","symbol":"RHHBY","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1690444800000,"name":null,"time":"Pre-Market","dateTimestamp":1690430400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RHHBY\",market:\"US\",,,undefined,":[{"executeDate":"2016-03-02","recordDate":"2016-03-04","paymentDate":"2016-04-22","value":0.837655,"currency":"USD"},{"executeDate":"2019-03-07","recordDate":"2019-03-08","paymentDate":"2019-03-18","value":0.691071,"currency":"USD"},{"executeDate":"2020-03-19","recordDate":"2020-03-20","paymentDate":"2020-03-30","value":0.7280819,"currency":"USD"},{"executeDate":"2021-03-18","recordDate":"2021-03-19","paymentDate":"2021-03-29","value":0.8108518,"currency":"USD"},{"executeDate":"2022-03-17","recordDate":"2022-03-18","paymentDate":"2022-03-28","value":1.2649619,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RHHBY\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.125,"buy":0.125,"hold":0.75,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":0.75,"analysts":8,"updateTime":1745899200000}}}